angiotensin ii has been researched along with 1-hexadecyl-3-trifluoroethylglycero-sn-2-phosphomethanol in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blair, IA; Dodia, C; Fisher, AB; Greineder, CF; Han, J; Hood, ED; Mesaros, C; Muzykantov, VR; Shuvaev, VV | 1 |
1 other study(ies) available for angiotensin ii and 1-hexadecyl-3-trifluoroethylglycero-sn-2-phosphomethanol
| Article | Year |
|---|---|
Antioxidant protection by PECAM-targeted delivery of a novel NADPH-oxidase inhibitor to the endothelium in vitro and in vivo.
Topics: Acute Lung Injury; Angiotensin II; Animals; Antibodies, Monoclonal; Antioxidants; Capillary Permeability; Enzyme Inhibitors; Glycerophosphates; Human Umbilical Vein Endothelial Cells; Humans; Immunoglobulin G; Lipopolysaccharides; Liposomes; Lung; Male; Mice; Mice, Inbred C57BL; NADPH Oxidases; Phospholipases A; Platelet Endothelial Cell Adhesion Molecule-1; Reactive Oxygen Species; Streptavidin; Tissue Distribution; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2012 |